first line chemotherapy
Showing 1 - 25 of >10,000
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
Cancer Of Pancreas Trial (Analyze of GemCore status)
Not yet recruiting
- Cancer Of Pancreas
- Analyze of GemCore status
- (no location specified)
Sep 19, 2023
HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)
Recruiting
- HR Positive HER2 Negative Advanced Breast Cancer
-
Tianjin, China天津市肿瘤医院
May 26, 2023
Pancreatic Tumors Trial in Shanghai (Utidelone injection in combination with gemcitabine)
Recruiting
- Pancreatic Neoplasms
- Utidelone injection in combination with gemcitabine
-
Shanghai, Shanghai, ChinaShanghai First People's Hospital
Mar 21, 2023
Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)
Not yet recruiting
- Breast Cancer
- Dalpiciclib combined with Letrozole
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 3, 2023
Malignant Pleural Mesothelioma Trial in Cairo (Gemcitabine, supportive care)
Not yet recruiting
- Malignant Pleural Mesothelioma
- Gemcitabine
- supportive care
-
Cairo, EgyptAin Shams University Hospital
Dec 20, 2022
NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)
Not yet recruiting
- Non-small Cell Lung Cancer Stage II
- +3 more
- Serplulimab combined with bevacizumab and first-line chemotherapy
-
Guangzhou, Guangdong, ChinaLikun Chen
Apr 10, 2023
Pancreatic Cancer, Ultrasonography, First-line Chemo Trial in Beijing (Contrast-enhanced ultrasound(CEUS))
Recruiting
- Pancreatic Cancer
- +2 more
- Contrast-enhanced ultrasound(CEUS)
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Feb 6, 2023
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint
Active, not recruiting
- Recurrent Nasopharyngeal Carcinoma
- +2 more
- PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
-
Guangzhou, Guangdong, ChinaYanqun Xiang
Sep 5, 2022
NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)
Completed
- Non-Small Cell Lung Cancer
- Brain Neoplasms
- bevacizumab
- +2 more
- (no location specified)
Dec 9, 2022
Colorectal Cancer, Colorectal Cancer Stage IV Trial (Fruquintinib Plus Capecitabine, Capecitabine)
Not yet recruiting
- Colorectal Cancer
- Colorectal Cancer Stage IV
- Fruquintinib Plus Capecitabine
- Capecitabine
- (no location specified)
Jul 9, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)
Completed
- Recurrent Cervical Carcinoma
- +5 more
- Chemotherapy plus apatinib
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Gallbladder Cancer Unresectable Trial in Lucknow (chemoradiation)
Recruiting
- Gallbladder Cancer Unresectable
- chemoradiation
-
Lucknow, Uttar Pradesh, IndiaSanjay Gandhi Postgraduate Institute of Medical Sciences
Aug 6, 2022
NSCLC Trial in Ostrava (primary tumour radiotherapy, stereotactic body radiotherapy, maintenance radiotherapy)
Recruiting
- Non-small Cell Lung Cancer
- primary tumour radiotherapy
- +2 more
-
Ostrava, Moravian-Silesian Region, CzechiaUniversity Hospital Ostrava
Dec 6, 2022
Carcinoma, Pancreatic Ductal, Prognosis Trial in Clichy, Lille, Saint-Cloud (Clinical value of 5 transcriptomic signatures to
Not yet recruiting
- Carcinoma, Pancreatic Ductal
- Prognosis
- Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC
- Biomarkers of tumor signatures (translational studies)
-
Clichy, France
- +2 more
Jul 25, 2022
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in Shanghai (Fluzoparib and Camrelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Nasopharyngeal Cancer
- Fluzoparib and Camrelizumab
-
Shanghai, Shanghai, ChinaFudan Universtiy Shanghai Cancer Centre
Jun 4, 2022
Tislelizumab Combined With Chemotherapy in First-line Treatment
Active, not recruiting
- Tislelizumab
- +3 more
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023
Non Small Cell Lung Cancer, Endostatin Trial in Guangzhou (Endostatin)
Not yet recruiting
- Non Small Cell Lung Cancer
- Endostatin
-
Guangzhou, Guangdong, ChinaAffiliated Cancer Hospital and Institute of Guangzhou Medical Un
Jul 4, 2022
Gestational Trophoblastic Tumors Trial in Hangzhou (Etoposide, actinomycin D, methotrexate)
Recruiting
- Gestational Trophoblastic Neoplasms
- Etoposide
- +7 more
-
Hangzhou, Zhejiang, ChinaWeiguo Lv
Jun 2, 2022
Esophagus Squamous Cell Carcinoma Trial in Beijing (Palbociclib, Afatinib)
Recruiting
- Esophagus Squamous Cell Carcinoma
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
May 17, 2023
Soft Tissue Sarcomas Trial in Zhengzhou (Anlotinib Hydrochloride)
Completed
- Soft Tissue Sarcomas
- Anlotinib Hydrochloride
-
Zhengzhou, Henan, ChinaAffiliated Cancer Hospital of Zhengzhou University&Henan Cancer
Mar 14, 2022
First-line Chemotherapy for Advanced Pancreatic Cancer
Recruiting
- Pancreatic Ductal Adenocarcinoma, PDAC
-
Shanghai, Shanghai, ChinaRuijin Hospital
Dec 10, 2021
Small Cell Lung Cancer (SCLC) Trial (Tarlatamab, Lurbinectedin, Topotecan)
Not yet recruiting
- Small Cell Lung Cancer (SCLC)
- Tarlatamab
- +3 more
- (no location specified)
Feb 21, 2023
Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))
Recruiting
- Gastrointestinal Neuroendocrine Carcinoma
- Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 1, 2023